循环外泌体mRNA、miRNA和lncRNA特征预测晚期胃癌患者新辅助化疗疗效
核心信息
- 论文英文标题: A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer
- 期刊: Mol Cancer
- 发表年份: 2022
- DOI: 10.1186/s12943-022-01684-9
- PMID/PMCID: 36510184; PMC9743536
研究概览
At present, there is no validated marker to identify the subpopulation of patients with advanced gastric cancer (AGC) who might benefit from neoadjuvant chemotherapy (NACT). Furthermore, we established a 6-exosome-RNA panel that could robustly identified responders from non-responders treated with fluorouracil-based neoadjuvant chemotherapy.
核心发现
At present, there is no validated marker to identify the subpopulation of patients with advanced gastric cancer (AGC) who might benefit from neoadjuvant chemotherapy (NACT).
In view of this clinical challenge, the identification of non-invasive biomarkers for efficacy prediction of NACT in patients with AGC is imperative.
Herein, we aimed to develop a non-invasive, liquid-biopsy-based assay by using an exosome-derived RNAs model based on multi-omics characteristics of RNAs.
We firstly used a multi-omics strategy to characterize the mRNAs, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) profiles of circulating exosome enriched fractions in responders to NACT paired with non-responders, using RNA sequencing.
Echo Biotech 角色
血浆外泌体分离鉴定+外泌体全转录组测序分析+qPCR验证
关联平台: Exoomics®
关联服务与能力: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV Whole-Transcriptome Sequencing, qPCR Validation
关联产品或试剂: 无明确产品引用
参考文献
原始论文: A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer Mol Cancer. 2022. DOI: 10.1186/s12943-022-01684-9. PMID/PMCID: 36510184; PMC9743536.